GSK plc
GSKHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, GSK plc focuses on Drug Manufacturers - General services and products. GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United. At a $101.38B market cap, GSK plc ranks as a large-cap company within healthcare. It operates through Commercial Operations and Total R&D segments.
Market Cap
$101.38B
Beta
0.30
P/E (TTM)
13.27
P/E (Fwd)
9.66
EPS (TTM)
$3.81
EPS (Fwd)
$5.23
ROE
40.9%
ROA
10.0%
Cash
$3.44B
Total Debt
$19.11B
Free CF
$3.02B
52W Change
21.3%
Annual Financials
Cash vs Debt
GSK plc carries $19.11B in total debt against $3.44B in cash reserves — debt is roughly 5.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $3.02B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 40.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $29.32B to $32.67B.
GSK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. GSK plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing GSK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.